Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Including Diffuse Intrinsic Pontine Glioma

NCT07589257 is registered in ClinicalTrials.gov with Guangzhou Virotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07589257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07589257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Multicenter Phase II Clinical Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Including Diffuse Intrinsic Pontine Glioma
Lead sponsor
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
May 7, 2026
Completion date
December 31, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, diffuse midline glioma, h3 k27m-mutant